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Background: The aim of the study was to evaluate total parathyroidectomy with trace amounts of parathyroid
tissue (30 mg) as a surgical option in secondary hyperparathyroidism (sHPT) treatment.
Methods: From January 2008 to March 2012, 47 patients underwent parathyroidectomy. Comparisons of demographic
data, symptoms, and preoperative or postoperative biochemistry were made between total parathyroidectomy with
trace amounts of parathyroid tissue autotransplantation group and total parathyroidectomy group.
Results: Out of 47 cases, 45 had successful operation. 187 parathyroid glands identified at the initial operation were
reported in 47 patients. 43 patients had been diagnosed with parathyroid hyperplasia, and 4 patients had a benign
adenoma. After operation, pruritus, bone pain and muscle weakness disappeared, also serum PTH and serum
phosphate were declined markedly as well. After discharge, two patients (in total parathyroidectomy group) were
readmitted because of postoperative hypoparathyroidism. Graft-dependent recurrence was not observed in an average
follow-up of 42 months.
Conclusions: Total parathyroidectomy with sternocleidomastoid muscle trace amounts of parathyroid tissue
autotransplantation is considered to be a feasible, safe and effective surgical option for the patients with sHPT.
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AutotransplantationBackground
SHPT is ubiquitous in patients with chronic kidney failure
treated by long-term dialysis. High parathyroid hormone
(PTH) levels can lead to 1) renal osteodystrophy, 2) calci-
phylaxis, 3) ectopic calcifications, 4) abnormal fat and sugar
metabolism, 5) refractory pruritis, and 6) anemia [1-3].
New treatments for sHPT include vitamin D analogues and
calcimimetics. When vitamin D analogues and calcimi-
metics fails, parathyroidectomy becomes necessary. Surgical
treatment of sHPT may involve various surgical approaches
[3-6]. Surgical options for the treatment of sHPT include* Correspondence: heqingqing@yeah.net
1Department of Thyroid and Breast Surgery, Jinan Military General Hospital of
PLA, No.25 Shifan Road, Jinan 250031, People's Republic of China
Full list of author information is available at the end of the article
© 2014 He et al.; licensee BioMed Central Ltd.
Commons Attribution License (http://creativec
reproduction in any medium, provided the ortotal parathyroidectomy, subtotal (3 1/2 gland) parathyroid-
ectomy and total parathyroidectomy with heterotopic auto-
transplantation. However, surgeons have been debating on
the optimal operative management for patients with sHPT,
and surgical consensus on the optimal procedure has not
been reached [7-10]. The aim of this study is to examine
our experience with patients who underwent total parathy-
roidectomy with or without trace amounts of parathyroid
tissue autotransplantation for sHPT.Methods
Patient eligibility and study design
We performed a retrospective study of 47 patients with
chronic renal failure, who experienced total parathyroid-
ectomy with or without sternocleidomastoid muscleThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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2012. There were 26 men and 21 women and their mean
age was 46 years old (range, 28–71). Forty-seven patients
underwent hemodialysis for an average of 8.9 years
(range 3–19 years). Heights dropped an average of 6 cm
in all patients. After stosstherapy with Calcitriol 2 μg,
twice per week, all symptoms such as pruritus, bony pain,
movement disorder, anorexia and kyphosis (Figure 1) were
getting progressively worse, with serum PTH and calcium
level exceeding the normal range. Our indications for
parathyroidectomy in symptomatic patients with sHPT in-
clude elevated levels of serum PTH (>1600 ng/L), persist-
ent hypercalcemia, intractable pruritus, osteodystrophy or
calciphylaxis, bone pain, and pathological fracture, large-
sized parathyroid glands (volume > 1.0 cm3) on ultrason-
ography, and/or hyperphosphataemia (>2.26 mmol/L).
Forty-seven sHPT haemodialysis patients provided
written informed consent for the study, and the study
was approved by the Jinan Military General Hospital Re-
search Ethics Board. The decision to perform total para-
thyroidectomy with or without autotransplantation was
based on a preoperative thorough discussion with the
patient. 14 patients chose total parathyroidectomy with
trace amounts of parathyroid tissue autotransplantation.
33 patients, not eligible for kidney transplantation,
underwent total parathyroidectomy.
Preoperative preparation
Forty- six patients showed 1–4 radionuclide dense areas
in the neck by 99mTc-MIBI SPECT scan. All cases had
routine preoperative tests including complete bloodFigure 1 Bone deformities.counts, serum electrolytes, chest x-ray, electrocardio-
gram, and coagulation screening. Surgical intervention
in the form of parathyroidectomy is generally considered
only in cases of severe sHPT. However, identification of
the exact location of the parathyroid glands before para-
thyroidectomy is challenging. The surgeon attended the
ultrasonography examination, which was helpful to get
an exact localization of parathyroid glands (by ultrason-
ography and scintigraphy) and perspicuous understand-
ing of their relationship with the surrounding tissues.
139 hyperplastic parathyroid glands were detected by B-
ultrasonography in 47 cases, 2 to 4 enlarged parathyroid
glands in each case. Two cases had cervical CT scanning
and two and three hyperplastic parathyroid glands were dis-
covered respectively. All cases had hemodialysis three times
per week and heparin-free hemodialysis was performed the
day before operation. Forty-seven patients underwent intra-
venous 99mTc-MIBI 2 hours prior to surgery.
Surgical procedure
All patients were operated under supervision of one sin-
gle surgeon. With the patients under anesthesia cervical
plexus and neck hyperextended, a Kocher's incision is
made, preferably in a skin crease. Tissues from skin to
muscles were dissected layer by layer until the thyroid
gland was exposed. Then the middle thyroid veins were
cut off, and the thyroid gland was turned over medially.
With the combination of preoperative ultrasonography,
intraoperative exploration, and intraoperative gamma
probe detection, all of the parathyroid tissues were care-
fully discovered and removed. The operation was per-
formed carefully avoiding any damage to the parathyroid
capsules. Resection of the surrounding fat tissue of ori-
ginal parathyroid glands is essential.
All removed tissues were intraoperatively verified by
frozen section. Surgical pathology reports of parathyroid
tissues removed were reviewed in all procedures per-
formed at our hospital. The resected tissues were kept in
sterilized iced saline. If fewer than four glands were
found, then total parathyroidectomy without autotrans-
plantation and transcervical thymectomy were under-
taken. Thymectomy was not performed routinely if four
parathyroid glands had been confidently identified.
Diffuse-type hyperplastic parathyroid tissue(no nodular
hyperplastic parathyroid tissue) was chosen for auto-
grafting. The estimated weight of the autograft tissue is
30 mg. After the strap muscles were closed, a 1.0 cm
pocket was developed parallel to sternocleidomastoid
muscle fibers. After it was certain that there was no
bleeding in the muscle pocket, 30 mg of parathyroid
gland (cutting into pieces of 1 mm3 in size) without
nodular hyperplasia was implanted into the muscular
bed of the patients' sternocleidomastoid muscle. The
muscle fibers anterior to the pocket containing the
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sorbable sutures, and the cephalad and caudad portions
of the autograft site were marked with titanic clips for
future reference, in case further reduction of functioning
parathyroid tissue became necessary. Care was taken not
to traumatize the area of the autograft during closure of
the incision, in an effort to avert bleeding into the area
that causing impaired revascularization of the parathy-
roid tissue.
Intraoperative PTH was performed trying to confirm
total removal of the parathyroid glands, so as to avoid
overlooking remaining or supernumerary glands. Periph-
eral venous blood sample (5.0 mL) was obtained imme-
diately after induction of anesthesia and 30 minutes after
removal of all parathyroid glands.
If the surgeon identifies 3 glands and cannot identify the
4th gland, or intraoperative PTH was greater than 400 ng/L,
complete cervical exploration of ectopic sites (explore
retropharyngeal and esophageal spaces, trace recurrent la-
ryngeal nerve into chest, open carotid sheath, and do not
perform median sternotomy) and cervical thymectomy
were performed [11,12].
Three patients had undergone thyroidectomy addition-
ally (one patient with papillary thyroid microcarcinoma
and 2 cases with diffuse Hashimoto thyroiditis and large
multinodular goiter).
Approximately 80 mg of the parathyroid tissue will be
placed in cold sterile saline solution (containing a solution
of 80% culture media, 10% patient serum and 10% dimethyl
sulfoxide) for later cryopreservation. The vial is then cooled
to −70°C at a decreasing rate of 1°C per minute.
Postoperative management
For the prevention of postoperative tetany, all patients
received oral or intravenous calcium (higher dialysate
Ca levels in 45 patients) if indicated. 45 patients were
given calcium supplement postoperatively through a
deep vein infusion pump to maintain adequate calcium
levels. The serum calcium concentration was monitored
every 12 hours to adjust the oral and/or intravenous
calcium treatment. Calcium gluconate of 8–16 g per
24 hours was administered for one to two weeks, then,
the rate and times of calcium infusion were adjusted ac-
cording to the results of serum calcium measurement to
maintain the serum concentration within the range of
1.8-2.3 mmol/L and finally until the serum calcium was
stabilized (usually in one to two weeks). Afterwards, oral
calcium administration (calcium carbonate of 3-12 g per
day) was prescribed. Meanwhile, postoperative oral Cal-
citriol was administrated with the dose of 0.25-2.5 μg
per day for one to three weeks, gradually diminished to
0.25-0.5 μg per day in total parathyroidectomy with
autotransplantation group, and 0.75-1 μg per day in total
parathyroidectomy group.Higher Ca dialysate is helpful to sustain normal serum
Ca levels. Parathyroid hormone was measured postoper-
atively, and heparin-free hemodialysis was resumed for
every patient, 24 hours postoperatively.
Patients were discharged when corrected calcium
levels were above 2.0 mmol/L and free of hypocalcemic
symptoms. Follow-up biochemical markers included
serum phosphate, calcium, levels of 25-Hydroxyvitamin
D3 (1,25-Hydroxyvitamin D3 is better, but now we are
inaccessible of this test, will be included later) and
PTH.
After discharge, a follow-up visits at 1, 3, 6, 12 months,
and every six months thereafter are executed. Follow-up
visits consist of telephone interview, in-clinic visits, dir-
ect mail, and email. A brief telephone questionnaire in-
cluding follow-up medical records and biochemistry
studies at local affiliated hemodialysis hospitals was used
to evaluate patients’ compliance with postoperative oral
calcium, Calcitriol and symptom relief.
Statistical analysis
The continuous data were tested by the t -test, and cat-
egorical data were tested by the chi-square test or Fisher’s
exact test. The statistical software used was Social Sciences
version 15.0. Differences were considered significant at
p-value <0.05.
Results
One hundred and eighty-seven parathyroid glands iden-
tified at the initial operation were reported in 47 patients
(Table 1). Thirty-three (35.1%) inferior glands were lo-
cated in the thymic tongue. 43 of the 47 patients had the
diagnosis of parathyroid hyperplasia, four patients had a
benign adenoma. 45 patients had 4 parathyroid glands
(Figure 2). More than 4 glands were discovered only in
one patient at the primary operation (Figure 3). Three
glands were removed in 1 patient. After operation, prur-
itus, bone pain and muscle weakness disappeared, and
serum PTH and serum phosphate were declined mark-
edly (Table 2).
Of 47 cases, 45 had successful operation. 2 patients had
persistent hyperparathyroidism in total parathyroidectomy
group(one patient was found the 5th supernumerary gland
in 1 year after the surgery, Figure 4). The detecting sensi-
tivity combined with preoperative 99mTc-MIBI-SPECT
scan, intraoperative gamma probe detection, intraoper-
ative PTH assay, and intraoperative exploration for
parathyroid glands was 95.7%. No recurrent laryngeal
nerve palsies were encountered. And there were no peri-
operative deaths. Complications were two cervical bleed-
ings following postoperative hemodialysis which needed
surgical intervention.
The duration of hospitalization was 10.5 days on
average. Graft-dependent recurrence was not observed.
Table 1 Demographics, symptoms, and preoperative or postoperative biochemistry
Parameter tPTX+AT Group (n=14) tPTX Group (n=33) P Value
Age, median (years) 46.5±13.9 (28–63) 45.8±14.2 (29–71) >0.05
Men/women 8/6 18/15 >0.05
Duration of dialysis (years) 9 (3–19) 8.8 (3–17) >0.05
Renal transplant (no.) 2 5 >0.05
Follow-up, mean (months) 43.1 ±8.9 (9–62) 41.6±10.4 (9–62) >0.05
Preoperative BMD (Z-score) −3.72±1.12 −3.66±0.98 >0.05
Symptoms
Fractures or bone pain (no.%) 14 (100) 33 (100) >0.05
Kidney stone (no.%) 0 0
Pruritus (no.%) 12 (85.7) 30 (90.9) >0.05
Fatigue/weakness (no.%) 8 (57.1) 20 (60.6) >0.05
Osteoporosis (no.%) 13 (92.8) 32 (96.9) >0.05
Preoperative biochemistry
PTH (ng/L) 2746 ± 886 (2430–3809) 2798 ±983 (1600–4280) >0.05
Ca (mmol/L) 2.6 ±0.21 (2.28-2.81) 2.58 ±0.23 (2.3-2.95) >0.05
P (mmol/L) 2.5 ±0.73 (1.75-3.91) 2.52 ±0.82 (1.77-4.31) >0.05
25(OH)D3(ng/ml) 10.31±2.35 10.45±2.41 >0.05
Postoperative 1st day biochemistry (n=31)
PTH (ng/L) 35.3±16.8 16.8±7.5 >0.01
Ca (mmol/L) 1.92 ±0.38 1.79±0.37 >0.05
P (mmol/L) 1.83±0.71 1.76±0.68 >0.05
Symptoms relief (no.%) (n=31)
Bone pain (no.%) 14 (100) 31 (100) <0.05
Pruritus (no.%) 12 (100) 30 (96.8) >0.05
Postperative BMD (Z-score) −2.83±1.92 −3.16±1.68 >0.05
Recurrence 0 0 <0.05
Postoperative symptomatic recurrent hypocalcemia 0 2 <0.05
Postoperative 6 months biochemistry (n=31)
PTH (ng/L) 13.69±6.29 8.87±6.15 <0.05
Ca (mmol/L) 2.01±0.19 1.91±0.21 <0.05
P (mmol/L) 0.895±0.18 0.95±0.22 <0.05
25(OH)D3 (ng/ml) 16.36±2.67 11.71±2.34 <0.05
Abbreviations: tPTX+AT total parathyroidectomy with autotransplantation, tPTX total parathyroidectomy, BMD bone mineral density, PTH parathyroid hormone, 25
(OH)D3 25-Hydroxyvitamin D3.
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fractures detected after a mean observation period of
42 months (range: 9–62 months). After discharge, two
patients (in total parathyroidectomy group) were re-
admitted because of postoperative symptomatic recur-
rent hypocalcemia (PTH:2.39 ng/L and 3.57 ng/L). One
patient who underwent kidney transplantation after
total parathyroidectomy with trace amounts of parathy-
roid tissue autotransplantation did not develop serious
hypocalcemia or osteomalacia. Rudimentary and split
glands were not present in all cases.Discussion
Chronic renal failure is a powerful stimulus for parathy-
roid cell proliferation. With the development of new
technologies, the survival time of the haemodialysis pa-
tients is being obviously extended. SHPT is a severe and
frequent complication in patients with advanced chronic
kidney disease, characterized by hyperaplasia of all para-
thyroid glands and elevated serum PTH levels [13,14].
Parathyroidectomy is only used when all medical therapy
(new therapeutic agents including vitamin D-receptor
activators and calcium-mimetics, and new phosphate
Figure 2 Four parathyroid glands identified at the primary
operation in patient for secondary hyperparathyroidism.
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rate of sHPT patients with parathyroidectomy indication
is unknown. Furthermore, in recent years contradictions
and disputes of physician-patient are increasingly inten-
sified in China. It is thought that the access of sHPT
patients to surgical treatment is limited and particularly
restricted to university centers. Parathyroidectomy indica-
tion is practically unequivocal. According to our experience,
the presence of extraskeletal calcification, calciphylaxis, de-
bilitating bone disease, refractory pruritus, severe hypercal-
cemia, and PTH >1600 ng/L are strong indications for
surgical treatment.Figure 3 Five parathyroid glands identified at the primary
operation in patient for secondary hyperparathyroidism.The best surgical approach for renal hyperparathyroid-
ism is yet to be determined and remains controversial in
the literature. There are three accepted main types of
surgical procedures and variations of these approaches
(subtotal parathyroidectomy, total parathyroidectomy,
and total parathyroidectomy with autotransplantation)
[15,16]. Every procedure has its own disadvantages be-
sides advantages. Sanbury [17] first described subtotal
parathyroidectomy in 1960, the major defect of subtotal
parathyroidectomy is that it is very difficult to recognize
which gland is suitable for preservation by observation
with naked eyes. This may cause recurrence of hyper-
parathyroidism. Once recurrence occurs, re-exploration
of the neck is required, thus there is a greater risk of in-
juring the recurrent laryngeal nerves than at the initial
operation, and reoperation also seems to introduce the
risk of parathyromatosis.
Total parathyroidectomy and autotransplantation (the
smallest gland was chosen) was first performed by Wells
in 1975 [18]. Small amounts of resected parathyroid tis-
sue can be autografted in the muscles of the forearm or
neck, as well as in the subcutaneous tissue of the chest
or abdomen. A randomized study suggested that total
parathyroidectomy with autotransplantation had a lower
rate of recurrent sHPT and an improved clinical out-
come compared to subtotal parathyroidectomy. Reopera-
tion was for persistent sHPT in 82 of 485 (17%).
Findings at reoperation included: autograft hyperplasia
(49%), supernumerary glands (20%), remnant hyperplasia
(17%), a missed in situ gland (7%), and a negative explor-
ation (5%). Reoperation determined that inadequate cer-
vical explorations occurred in 42% of patients who had
undergone a subtotal parathyroidectomy and in 34% of
patients who had undergone a total parathyroidectomy
with autotransplantation [14]. Tominaga who had the
biggest series consisting of 2660 patients reported that
graft-dependent recurrent sHPT was 248(9.3%), and 216
(8.1%) patients underwent only removal of the autograft
and 32 (1.2%) required both removal of the autograft
and resection of residual parathyroid gland in the neck
or mediastinum [19]. We thought that 30 pieces of 1 × 1
× 3 mm parathyroid tissue was more than 30 mg for
autografting. Operative failures occur because of the lim-
itations in preoperative localization, inadequate explor-
ation, and the natural history of hyperplastic parathyroid
tissue. Although we were unable to identify the superior-
ity of one operation over the other, operative success can
be improved with an adequate cervical exploration. We
believe sternocleidomastoid muscle is a better autograft-
ing area because of easy accessibility, one operative site,
less graft ischemia, low incidence of infection, and high
success rate due to excellent blood supply. But, sterno-
cleido-mastoid muscle is not the standard site for auto-
transplantation in secondary hyperparathyroidism. In the
Table 2 187 parathyroid glands identified at the primary operation in 47 patients for secondary hyperparathyroidism
Located in behind the thyroid gland No. of parathyroid glands The size (mm) The volume (mL)
Right superior parathyroid gland 47 5-22(9.1±4.1) 0.5-2.2(0.9±0.4)
Right inferior parathyroid gland 47 18-35(24±4.8) 1.7-3.6(2.1±0.5)
Left superior parathyroid gland 46 5-20(8.8±3.7) 0.6-2.1(1.1±0.47)
Left inferior parathyroid gland 47 15-33(21±4.9) 1.6-3.5(2.2±0.8)
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imaging modality that enabled reliable and precise
localization of the parathyroid) is able to distinguish
between a cervical recurrence and a graft depending re-
currence. Diffuse-type hyperplastic parathyroid tissue
preferably was chosen for autografting to prevent recur-
rent sHPT. Recurrent HPT after total parathyroidectomy
with autotransplantation is usually due to overgrowth of
the autograft. We consider thirty pieces of 1 × 1 × 3 mm
parathyroid tissue (about 100 micrograms) too much.
Ten pieces of 1 × 1 × 3 mm parathyroid tissue (about 30
micrograms) is enough. For patients who demand long-
term hemodialysis after parathyroidectomy, the risk of
recurrence is not negligible. Thus, to avoid recurrent
HPT, all parathyroids, including supernumerary glands,
should be identified. In our series, 35.1% of inferior
glands were located in the thymic tongue. If the surgeon
cannot identify 4 glands, removal of thymic tissue from
the neck incision is essential to avoid missing glands.
Most patients underwent artificial arteriovenous fistula
in bilateral forearms for hemodialysis. We believe it
would be easier and safer to remove residual parathyroid
tissue from sternocleidomastoid muscle at recurrence asFigure 4 The 5th parathyroid gland was confirmed by positive
sestamibi 99 mTc investigation in the mediastinum in 1 year
after the surgery.compared to from the forearm. Reoperation may be rela-
tively simple for recurrent hyperparathyroidism induced
by the hyperfunction of autografted parathyroid tissue,
because surgical access to sternocleidomastoid muscle is
simple, and it does not require general anesthesia, also
avoid the risk of major surgical complications such as la-
ryngeal nerve injury.
In order to suppress parathyroid secretion completely
and reduce recurrent hyperparathyroidism, total parathy-
roidectomy without autotransplantation was performed
in 1967 [20]. Patients who had total parathyroidectomy
without autotransplantation had temporary hypocalcemia
postoperatively and became asymptomatic, despite hypo-
calcemia, when they were supplemented with calcitriol in
the long term. After all types of surgery, attention must be
kept on patients' postoperative period. The lack of osteo-
clastic activity caused by a decrease in PTH postopera-
tively may lead to a precipitous fall in calcium levels, a
condition called “hungry-bone syndrome” [21]. While the
autographed parathyroid tissue begins to function in two
to three weeks, patients may have severe hungry bone
syndrome in this period. It is necessary that all patients
received calcium and calcitriol supplement for low
calcium levels.
The function of the grafted tissue can be followed in
most patients by the determination of the PTH concen-
tration. In 14 of our cases we perform trace amounts of
parathyroid tissue (30 mg) autotransplantation and in
follow-up (9–62 months) no recurrence observed. The
sPTH level has been used to evaluate the results of para-
thyroidectomy. Ideally, the completeness of the oper-
ation could be biochemically confirmed by utilizing the
intraoperative PTH assay. If intraoperative PTH is more
than 400 ng/L, supernumerary parathyroid gland may
not be completely resected. The extent of operative ex-
ploration for supernumerary glands may become less
controversial with widespread utilization of the intraop-
erative PTH assay as an adjunct in guiding the com-
pleteness of resection. The utilization of intraoperative
PTH monitoring may become a useful adjunct for assur-
ing that the patient has undergone an adequate parathy-
roidectomy in sHPT [22-26]. Patients whose PTH level
dropped under 400 ng/L by the removal of parathyroid
gland, sHPT could be controlled by medical treatment
after the operation. Patients who underwent total para-
thyroidectomy without autotransplantationusually had
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gery, but later it can be detected again. The rise in serum
PTH may be a result of parathyroid cell re-proliferation
stimulated by hypocalcemia in these patients. A similar
biochemical rebounding tendency was observed. In our
study, clinical symptom relief has no statistical difference
between total parathyroidectomy with trace amounts of
parathyroid tissue autotransplantation group and total
parathyroidectomy group. Bone pain disappeared in al-
most all patients within 1 week after surgery. Total para-
thyroidectomy without autotransplantation leads to
harmful definitive hypoparathyroidism condition. Clin-
ical experience showed that total parathyroidectom had
disadvantages, such as candidate for kidney transplant-
ation, lifelong substitution therapy, and osteopenia de-
veloped in the absence of PTH [6,15,26,27].
Conclusions
The total parathyroidectomy with trace amounts of
parathyroid tissue autotransplantation is a feasible, safe
and effective surgical option for the patients with sHPT.
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